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Women become infertile approximately 10 years before menopause, and as more women delay childbirth into
their 30s, the number of women who experience infertility is likely to increase. Tests that predict the timing of
menopause would allow women to make informed reproductive decisions. Current predictors are only effec-
tive just prior to menopause, and there are no long-range indicators. Age at menopause and early menopause
(EM) are highly heritable, suggesting a genetic aetiology. Recent genome-wide scans have identiﬁed four loci
associated with variation in the age of normal menopause (40–60 years). We aimed to determine whether
theses loci are also risk factors for EM. We tested the four menopause-associated genetic variants in a
cohort of approximately 2000 women with menopause ≤45 years from the Breakthrough Generations
Study (BGS). All four variants signiﬁcantly increased the odds of having EM. Comparing the 4.5% of individ-
uals with the lowest number of risk alleles (two or three) with the 3.0% with the highest number (eight risk
alleles), the odds ratio was 4.1 (95% CI 2.4–7.1, P 5 4.0 3 10
27). In combination, the four variants discrimi-
nated EM cases with a receiver operator characteristic area under the curve of 0.6. Four common genetic var-
iants identiﬁed by genome-wide association studies, had a signiﬁcant impact on the odds of having EM in an
independent cohort from the BGS. The discriminative power is still limited, but as more variants are discov-
ered they may be useful for predicting reproductive lifespan.
INTRODUCTION
Earlier menopause is associated with a decreased risk of breast
cancer, but an increased risk of osteoporosis and cardiovascu-
lar disease (1). There is also a signiﬁcant impact on fertility
associated with early menopause (EM), which is particularly
relevant to current populations where delaying childbearing
has become more prevalent. The number of births per 1000
British women is now greater for those in their early 30s
than it is for women in their early 20s (2,3). Fertility decreases
long before the onset of menopause, beginning on average at
about the age of 30 years. It is estimated that natural fecundity
ceases at a mean age of 41 years, i.e. 10 years before meno-
pause, and therefore women who are destined to have an
EM and who delay childbearing until their 30s are more
likely to have problems conceiving (4).
Natural, non-surgical, menopause occurs at a mean age of
51 years in Caucasian populations, with a roughly normal dis-
tribution between 40 and 60 years, but a tail below 40 years
(5,6). Menopause before the age of 40, or premature ovarian
failure (POF), occurs in 1% of the population (6). Menopause
before 45 years occurs in  5% of women and is often termed
‘EM’. Menopause is initiated by a fall in the number of
oocytes in the ovary below a threshold level of about 1000
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Advance Access published on October 17, 2010(7). However, loss of oocytes occurs throughout female life
with maximal numbers present before birth: approximately
6 million oocytes are present at 6 months gestation. By
puberty, the number has decreased to  400 000. Only a
small proportion of oocytes are lost through ovulation, and
the majority of the reduction is by atresia. The rate of
atresia increases with age, particularly in the 10 years prior
to menopause (8). The current methods for predicting age at
menopause are reliant on detecting the peri-menopausal
changes in oocyte number and are therefore poor long-range
predictors (9). Hormonal serum levels alter prior to meno-
pause, including follicle-stimulating hormone (FSH), antimul-
lerian hormone (AMH) and inhibin B. Of these, AMH is the
best long-term predictor, with levels decreasing approximately
10 years before menopause (10,11). In addition to endocrine
markers, other markers of ovarian reserve are antral follicle
count and ovarian volume (9). Genetic predictors of menopau-
sal age have the obvious advantage of being present from birth
and thus have the potential to offer women advice about their
reproductive lifespan from an early age, enabling them to
make informed reproductive choices.
The heritability of menopausal age has been estimated to be
between 30 and 85%, indicating a substantial genetic com-
ponent to this complex trait, and a signiﬁcant proportion
(15–30%) of POF cases are familial, suggesting a genetic
aetiology (12–15). Recent genome-wide association studies
(GWAS) have been very successful in identifying genetic
loci for many complex traits. Two independent studies, inves-
tigating age at menopause, published their data in 2009 and
between them identiﬁed four loci associated with normal age
of menopause variation, on chromosomes 19, 20, 6 and 5
(16,17). In each of the GWAS, women with menopause
before 40 years were excluded. Although genes involved in
POF may also regulate menopausal age in the normal range,
it is possible that there is a different genetic aetiology for
women with EM. Hence, we tested the newly identiﬁed
genetic variants associated with normal variation in menopau-
sal age, in a population of approximately 2000 women from
the Breakthrough Generations Study (BGS) who had EM,
deﬁned as menopause before the age of 46 years, plus 2000
matched controls. The BGS has not been included in any of
the discovery of GWAS and thus represents a completely inde-
pendent cohort. We included estimates of the effects of com-
bining information from all four variants to calculate the
cumulative genetic effect and assess the usefulness of these
variants as predictors of menopausal age and their potential
for assisting reproductive choice for young women, prior to
oocyte depletion.
RESULTS
Four common genetic variants inﬂuence menopausal age
by between 0.7 and 11 months per allele
Using menopause age as a quantitative trait, the directions of
association and effect sizes of all four single nucleotide poly-
morphisms (SNPs) were consistent with those published in the
GWAS (Table 1). The effect sizes for all SNPs were slightly
lower than that in the discovery GWAS, as expected due to
‘winners curse’, but the chromosome 19 and 20 hits in
particular have substantial effects on age at menopause with
a reduction in the menopausal age of 3 months (0.257 years)
and an increase of 11 months (0.924 years) per allele, respect-
ively. Using the adjusted R
2 from the regression model, we
calculated that together the four variants explained 1.4% of
the variance in menopause age in controls.
Menopause variants are associated with EM
All four SNPs were associated with an increased risk of
menopause before the age of 46, with the risk allele consistent
with the GWAS, i.e. being the allele associated with decreasing
menopausal age. The odds ratios (ORs) per allele for each SNP
ranged from 1.13 to 1.85, the non-synonymous SNP on chromo-
some 20 having the largest effect (Table 2). When comparing
homozygote groups, the ORs ranged from 1.35 to 2.8. Three
percent of women were homozygous for all four risk variants;
of these 97 women, 66 (68%) were in the EM group and 31
(32%) were controls. We calculated the expected ORs for EM
based on the quantitative trait estimates from the ReproGen
GWAS and the BGS controls, and there was evidence that
rs4806660 had a larger OR for EM than predicted [observed
OR ¼ 1.45 (CI 1.32–1.59) versus expected OR ¼ 1.20 (CI
1.17–1.23), P ¼ 0.0001] (Supplementary Material, Table S2).
Menopause variants are associated with POF
There were 260 women in the BGS cohort with POF and we
determined the association with the menopause SNPs in these
women. We were not well powered to detect the effects, but
for all four SNPs there was evidence that the odds of being a
POF case, per risk allele, were not signiﬁcantly different from
the odds of being an EM case excluding POF (P . 0.05)
(Table 2). The smallest P-value in this analysis was for
rs16991615, with P ¼ 0.051. There was also nominal evidence
that the rs16991615 SNP had a lower OR for POF than would
be expected from the quantitative trait estimates [observed
Table 1. Association of GWAS menopause SNPs with age of natural menopause in BGS controls, i.e. menopause .45 years, excluding those with surgical
menopause (n ¼ 1261)
SNP chr Minor allele Allele 2 MAF in controls (%) ReproGen GWAS, per-allele effect BGS controls
Per-allele effect (se) P-value
rs4806660 19 C T 36.5 20.406 (0.03) 20.257 (0.12) 0.027
rs16991615 20 A G 7.0 0.971 (0.0624) 0.924 (0.23) 0.000056
rs9379896 6 C T 18.5 0.242 (0.0377) 0.121 (0.14) 0.39
rs244715 5 A G 45.9 0.291 (0.0334) 0.059 (0.12) 0.64
Effect sizes are in years and are per copy of the minor allele.
Human Molecular Genetics, 2011, Vol. 20, No. 1 187OR ¼ 1.3 (CI 0.88–1.92) versus expected OR ¼ 2.08 (CI
1.90–2.29), P ¼ 0.02] (Supplementary Material, Table S2).
Increased odds of having EM when menopause risk alleles
are combined
Combining all risk alleles into an allele score gave a per-allele
increased odds of being in the case group of 1.34 (95% CI
1.26–1.43, P ¼ 2.2 × 10
220) (Fig. 1). Weighting each risk
allele by effect size did not appreciably alter the OR (OR ¼
1.38, 95% CI 1.29–1.48, P ¼ 1.1 × 10
219); therefore,
results are presented for the unweighted alleles.
When risk alleles were combined, there were signiﬁcantly
increased odds of having EM in individuals with eight risk
alleles compared with the median number in the control popu-
lation of ﬁve risk alleles (OR ¼ 2.02, 95% CI 1.30–3.15, P ¼
0.002) (Fig. 2). We also compared individuals at the extremes
of the risk allele distribution and determined the increased
likelihood of being a case: comparing the 4.5% of individuals
with the lowest number of risk alleles (two or three) with the
3.0% with the highest number (eight risk alleles), the OR was
4.1 (95% CI 2.4–7.1, P ¼ 4.0 × 10
27). Comparing the 18.8%
of women with less than ﬁve risk alleles with the 19.1% with
more than six, the difference was also signiﬁcant (OR ¼ 2.9,
95% CI, 2.3–3.6, P ¼ 4.6 × 10
219).
Combined risk alleles have 60% discriminatory power
The discriminative power of the four menopause SNPs for EM
was calculated by determining the area under the curve (AUC)
in a receiver operator characteristic (ROC) analysis. Combin-
ing all four SNPs gave an AUC of 0.6 (Fig. 3).
DISCUSSION
It is well established that EM can have a genetic aetiology, but
few loci have been identiﬁed. Four loci associated with vari-
ation in the normal age of menopause were recently identiﬁed
by two independent GWAS with very robust statistical evi-
dence (16,17) and we investigated the role of these common
variants in EM.
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Figure 1. Number of EM risk alleles for all four SNPs in women with meno-
pause at 45 and below (EM) compared with women who had menopause after
the age of 45 years (controls).
188 Human Molecular Genetics, 2011, Vol. 20, No. 1The four published variants had similar effects on age at
menopause as observed in the two published discovery
studies and our unpublished data from ReproGen, although
in each case the effect was smaller, which is consistent with
other GWAS, where the discovery effect is larger than in repli-
cation cohorts due to over-inﬂation or ‘winners curse’. Two of
these variants, on chromosomes 19 and 20, were signiﬁcant at
P , 0.05, but we had ,20% power to detect the observed
effect sizes at P , 0.05 for the SNPs on chromosomes 5 and
6. Together, the four SNPs explain about 1.4% of the variation
in age at menopause. This is comparable to other complex
traits such as height and BMI: 20 variants explain about 3%
of the variation in height (18) and the 17 variants published
to date for BMI only explain about 1% of the variation (19).
Our data suggest that variants associated with normal
menopausal age are also signiﬁcant risk factors for EM. The
non-synonymous SNP in MCM8 (rs16991615) increased the
risk of EM by 85% per allele, the rare allele being protective
for EM. The chromosome 19 variant near TMEM224
(rs4806660) also has a substantial effect on risk of EM,
increasing the OR by 45%. These ORs are higher than many
reported for complex traits, which generally have per-allele
ORs less than 1.5, with the exception of autoimmune dis-
orders, macular degeneration and pigmentation loci (20)
(http://www.genome.gov/gwastudies); however, further repli-
cation in additional EM cohorts would be beneﬁcial in order
to conﬁrm the effects.
It has been hypothesized that EM cases may have a different
aetiology from normal menopause. Our data suggest that there
is at least some common aetiology between EM and normal
menopause as the same genetic loci are associated with both
traits. However, the OR for the chromosome 19 SNP was sig-
niﬁcantly greater than predicted, based on the effect on meno-
pause age in the normal range in the quantitative trait analysis,
suggesting that this locus may have a non-linear effect on
menopause age. We investigated the aetiology of EM further
in women at the extreme of the menopause distribution, i.e.
menopause before 40 years. Women who have menopause
before 40 are clinically classiﬁed as having POF and are
often investigated for a genetic aetiology, most commonly
by cytogenetic screening and FMR1 mutation testing. The
published menopause variants were originally identiﬁed in
women excluding those with POF. The chromosome 20 SNP
was the only variant where there was a suggestion that the
effect might be different in POF cases compared with other
EM cases, as the OR for POF cases was lower than predicted
from the quantitative trait estimates and did not overlap the
95% conﬁdence interval for EM, but with the caveat that
this SNP is rare (MAF ¼ 7%) and the number of POF cases
was relatively small. However, these data suggest that the
effect of the chromosome 20 SNP is not as strong in POF
cases and suggest that POF may have a different aetiology.
Our data therefore provide evidence that while some EM
cases represent the tail of the normal distribution, some may
have a different aetiology. The role of menopause variants
in POF requires replication in additional independent
studies, but these preliminary data support the necessity to
look for EM-speciﬁc genes as these may not overlap with
genes for menopause in the remainder of the age distribution.
EM has a signiﬁcant impact on female health and results in
early infertility. Current techniques have good predictive
power for the end of female reproductive life, but only in
the immediate pre-menopausal period when ovarian reserve
is already diminished and natural conception is likely to be
difﬁcult or impossible. Commercial over-the-counter tests
are available that measure hormone levels, usually FSH and/
or AMH, but they need to be repeated every 2 years and are
not good long-range predictors. It would be beneﬁcial for
women to be able to predict the timing of the end of their
reproductive life in their early 20s, so that they can decide
whether they want to risk the chance of infertility by delaying
childbearing. The high heritability of menopausal age makes
the potential for a genetic test extremely attractive. Very
few genes have been demonstrated to be common causes of
EM, with the possible exception of the FMR1 premutation
gene which accounts for  5% of idiopathic POF cases (21),
but the utility of FMR1 as a genetic predictor has yet to be
proved (22). We therefore studied the discriminative power
of the four menopause loci identiﬁed by GWAS. The AUC
for the ROC analysis was 0.6 for the four variants in combi-
nation, which is still some way from the power of tests such
as the Framingham risk score for predicting coronary heart
disease, where the AUC is typically near 0.8. The genetic
power to discriminate EM cases is, however, comparable to
other genetic risk predictors, e.g. recent estimates for breast
cancer, where 10 variants have an AUC of 59.7% (23) and dia-
betes, where the AUC is 55–60% (24,25). Although the pre-
dictive power of the current variants is limited, as more
variants are discovered this should increase, and in the
absence of other good predictors for menopause, a genetic
score would have value, because it could be carried out
early and would be relatively inexpensive.
MATERIALS AND METHODS
Study population
We selected 2118 women with natural menopause before
the age of 46 years and 1941 controls with menopause after
45 years, from the BGS. The BGS is a prospective
Figure 2. ORs of EM for each number of risk alleles compared with the
median number of ﬁve risk alleles (indicated by a square). ORs are plotted
as diamonds and 95% conﬁdence intervals are indicated with vertical lines.
Human Molecular Genetics, 2011, Vol. 20, No. 1 189epidemiological cohort study launched in September 2004, the
primary objective of which is to investigate the environmental,
behavioural, hormonal and genetic causes of breast cancer and
which is also investigating the causes of other cancers and
diseases (http://www.breakthroughgenerations.org.uk/). The
cohort consists of over 110 000 women from the general popu-
lation of the UK aged 16 and older at the date of entry.
Recruitment is through volunteers connected with the charity
Breakthrough Breast Cancer, volunteers responding to publi-
city and via them their friends, family members and other con-
tacts. Each participant completes a questionnaire and most
provide a blood sample for analysis of genomic, hormonal
and other blood factors. Participants are asked questions that
include detailed menstrual histories, thus enabling identiﬁ-
cation for the present analyses of a group. Natural menopause
was deﬁned as absent menstruation for at least 6 months
without known cause. Women were excluded if periods
stopped because of pregnancy, breastfeeding, surgery, hormo-
nal contraceptive use and other types of medical treatment or
if there was a medical condition or illness that could have
caused amenorrhoea (e.g. polycystic ovary syndrome). We
selected one control for each EM case, matched for date of
birth (within 12 months), ethnicity, year of questionnaire com-
pletion and source of recruitment. Women were eligible as
controls if they were post-menopausal at entry to the study
with a menopausal age of 46 or over (74.3%) or if they
were pre-menopausal and entered the study aged 46 and
over (25.7%). Menopause could be natural or surgically
induced provided there was evidence they were still menstru-
ating after age 45. There were 182 women who had surgical
menopause in the control group. There were 126 cases who
were ,46 years old at entry to the study and controls aged
46 at entry were selected for each of these. We excluded
women with a history of breast cancer as cases and controls.
When multiple individuals from one pedigree were available,
we included only one individual—the youngest who met the
above criteria. Details of the ﬁnal genotyped population are
given in Table 3.
Genotyping
Following the publication of the four variants associated with
age at menopause, the research groups involved formed a con-
sortium and have pooled data and meta-analysed results. Thus,
the signals have been reﬁned, and for three of the four signals,
a different SNP became the strongest association signal in the
region and was selected for this analysis (ReproGen Consor-
tium, unpublished data). The linkage disequilibrium between
the tested and published SNPs was as follows: rs244715 and
rs365132: R
2 ¼ 0.677, rs4806660 and rs1172822: R
2 ¼
0.965, rs9379896 and rs2153157: R
2 ¼ 0.194. All samples
were therefore typed for the following four SNPs:
rs16991615 (chr 20, position 5 896 227) rs9379896 (chr 6,
position 10 994 935), rs4806660 (chr 19, position
60 516 446), rs244715 (chr 5, position 176 436 169). Genotyp-
ing was performed in-house using TaqMan PCR assays
designed by Applied Biosystems. Genotype frequencies were
in Hardy–Weinberg equilibrium (P . 0.1), call rates were
.93%, with .99% concordance of 288 duplicates.
Analysis
In order to determine the effect size of the published genetic
variants (16,17) on menopausal age without the bias of the
‘winner’s curse’ (26), we analysed the association of the
SNPs with normal menopausal age as a quantitative trait, in
the BGS controls (menopausal age .45 years), who had a
natural menopause. Thus, we excluded the 182 women who
had surgical menopause .45 years and the 498 women who
were not yet menopausal, leaving a cohort of 1261 women
Figure 3. ROC plot modelling the discriminatory power of all four menopause SNPs, for EM (≤45). On the y-axis is the true-positive rate or sensitivity of the
test for predicting EM and on the x-axis is the false-positive rate or speciﬁcity of the SNPs for predicting EM.
190 Human Molecular Genetics, 2011, Vol. 20, No. 1with natural menopause from the control group. Linear
regression was used to determine the effect of the minor
allele for each SNP on menopausal age. A combination of
all four variants in one model was used to estimate the var-
iance in menopause age explained by the SNPs, using the
adjusted R
2 value.
We performed additional analysis by subdividing the EM
cohort group into: (i) POF, i.e. women with menopause ,40
years; (ii) women with menopause between 40 and 45 years
inclusive (Table 3). We compared each case group with the
controls, i.e. women who were either non-menopausal but
over 45 years at entry into study or had gone through meno-
pause aged over 45. Logistic regression was used to determine
the effect of menopause-lowering alleles of each SNP on the
odds of being in the case group, assuming an additive
genetic model. We repeated the logistic regression excluding
non-white individuals (n ¼ 39). In addition, we performed
conditional logistic regression to account for matched pairs
of case–control samples. The ORs were very similar in the
conditional regression and excluding non-whites, when com-
pared with the unconditional regression including non-whites
(Supplementary Material, Table S1); we therefore present
results for unconditional logistic regression and included all
individuals in subsequent analyses.
We estimated the expected OR for each of the four variants
for both the EM (,46 years) and POF (,40 years) groups
based on the beta estimate from the ReproGen Consortium
GWAS (unpublished data) and compared with the ORs we
observed in the BGS. We also calculated the expected ORs
based on the quantitative trait analysis in BGS controls, but as
the menopause distribution is truncated at 45 years in this
cohort and the sample size is relatively small, we consider the
GWAS estimate to be more accurate. We calculated the
expected ORs for both the point estimate quantitative trait
beta and the upper and lower 95% CI intervals, by using
the ‘Case–Control for threshold-selected quantitative traits’
analysis on the Genetic Power Calculator website (http://
pngu.mgh.harvard.edu/~purcell/gpc/). Using the proportion of
variation explained by an SNP and the allele frequency, the
programgeneratesexpectedallelefrequenciesincasesandcon-
trols,wherecasesandcontrolsaredeﬁnedbystandarddeviation
thresholds. We then tested for heterogeneity (using Cochrans’s
Q-test in StatsDirect) between the expected and observed ORs.
The total number of risk alleles for EM, across all four
SNPs, was calculated and those with menopause below 46
years were compared with controls. Individuals were only
included if they were successfully genotyped for all four
SNPs (n ¼ 3242, of which 48% were controls). We deter-
mined the increased likelihood of being a case depending on
the number of risk alleles using logistic regression. In addition,
we compared individuals at the extreme 5 and 20% of the risk
allele distribution. We also compared ORs for the number of
risk alleles compared with the median number of alleles in
controls, i.e. 5. In a further analysis, we calculated a weighted
risk score based on the effect size of each variant: the number
of risk alleles at each locus was multiplied by its per-allele
effect size calculated from the quantitative trait analysis in
controls. The weighted score was then re-scaled to reﬂect
the number of SNPs tested, by dividing the weighted score
by the sum of the effects (1.348) and multiplying by the
number of SNPs (i.e. 4).
The power of the SNPs to discriminate EM cases was calcu-
lated by determining the AUC in an ROC analysis in Stata,
including all SNPs as separate linear terms in the model,
against menopause status, i.e. case (≤45) versus control.
The AUC measures how well the model discriminates
between cases and controls, such that a perfect test gives an
AUC of 1.0 and a test with no predictive power gives an
AUC of 0.5.
Adjusting by smoking status, a signiﬁcant predictor of
menopause status (27,28), did not inﬂuence our results; there-
fore, all data are presented without correction for smoking
status. Data were analysed in Stata v10.1 (http://www.stata.
com/).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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